@article{e5b6d4b8270144a5bd51da59be755efe,
title = "Treatment patterns, glycemic control and bodyweight with canagliflozin 300 mg versus GLP1RAs in Type II diabetes patients",
abstract = "Aim: Real-world effectiveness of canagliflozin 300 mg versus glucagon-like peptide-1 receptor agonists (GLP1RAs) was examined in patients with Type II diabetes. Patients & methods: Patients were selected from the Optum integrated database of administrative claims and electronic health record data (1 January 2013 to 31 March 2015). Results: Patients were less likely to discontinue (p < 0.0001) or switch (p = 0.0048), more likely to add-on treatment (p = 0.0314), and achieve HbA1c <8.0% (p = 0.0364) or weight loss ≥5% (p < 0.0001) with canagliflozin versus GLP1RAs over 9 months. Mean HbA1c was similar at 3-month intervals over 9 months with canagliflozin and GLP1RAs. Conclusion: Patients were less likely to discontinue or switch with canagliflozin than GLP1RA, and were more likely to add-on. Canagliflozin patients were more likely to achieve HbA1c <8.0% and weight loss ≥5% than GLP1RA patients.",
keywords = "HbA1c, Type II diabetes mellitus, adherence, canagliflozin, glucagon-like peptide-1 receptor agonist, weight loss",
author = "Coleman, {Craig I.} and Shivani Pandya and Li Wang and Onur Baser and Jennifer Cai and Mike Ingham and Brahim Bookhart",
note = "Funding Information: This study was funded by Janssen Scientific Affairs, LLC. Canagliflozin has been developed by Janssen Research & Development, LLC, in collaboration with Mitsubishi Tanabe Pharma Corporation. CI Coleman has received research support from Janssen Pharmaceuticals, Inc. and Boeheinger Ingelheim, Inc. S Pandya and L Wang are employees of STATinMED Research, which has a business relationship with Janssen. O Baser was an employee of STATinMED Research, which has a business relationship with Janssen, at the time of the study. M Ingham and B Bookhart are employees of Janssen Scientific Affairs, LLC, which funded this study, and are stockholders of Johnson and Johnson. J Cai was an employee of Janssen Scientific Affairs, LLC, at the time of the study. The study sponsor supported the conduct of the study and its publication. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Medical writing support was provided by Dana Tabor, PhD, of MedErgy, and was funded by Janssen Scientific Affairs, LLC. Funding Information: This study was funded by Janssen Scientific Affairs, LLC. Canagliflozin has been developed by Janssen Research & Development, LLC, in collaboration withMitsubishi Tanabe Pharma Corporation. CI Coleman has received research support from Janssen Pharmaceuticals, Inc. and Boeheinger Ingelheim, Inc. S Pandya and L Wang are employees of STATinMED Research, which has a business relationship with Janssen. O Baser was an employee of STATinMED Research, which has a business relationship with Janssen, at the time of the study. M Ingham and B Bookhart are employees of Janssen Scientific Affairs, LLC, which funded this study, and are stockholders of Johnson and Johnson. J Cai was an employee of Janssen Scientific Affairs, LLC, at the time of the study. The study sponsor supported the conduct of the study and its publication. Publisher Copyright: {\textcopyright} 2019Janssen Scientific Affairs, LLC.",
year = "2019",
doi = "10.2217/cer-2019-0002",
language = "English (US)",
volume = "8",
pages = "889--905",
journal = "Journal of Comparative Effectiveness Research",
issn = "2042-6305",
publisher = "Future Medicine Ltd.",
number = "11",
}